Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors
Autor: | X. Margaret Liu, Herbert Chen, Eric Y. Cheng, Tolulope A. Aweda, Danilea M. Carmona Matos, Jason Whitt, Renata Jaskula-Sztul, Alexander W. Chang, Rachael Guenter, Suzanne E. Lapi |
---|---|
Rok vydání: | 2019 |
Předmět: |
Cancer Research
endocrine system endocrine system diseases medicine.drug_class 030209 endocrinology & metabolism lcsh:RC254-282 Article Romidepsin 03 medical and health sciences 0302 clinical medicine In vivo medicine Somatostatin receptor 2 Lung cancer neoplasms histone deacetylase inhibitor Somatostatin receptor business.industry Histone deacetylase inhibitor medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens digestive system diseases 3. Good health somatostatin receptor Somatostatin Oncology neuroendocrine cancer 030220 oncology & carcinogenesis Cancer research Histone deacetylase business pulmonary carcinoid medicine.drug |
Zdroj: | Cancers Volume 11 Issue 6 Cancers, Vol 11, Iss 6, p 767 (2019) |
ISSN: | 2072-6694 |
Popis: | Pulmonary carcinoids are a type of neuroendocrine tumor (NET) accounting for 1&ndash 2% of lung cancer cases. Currently, Positron Emission Tomography (PET)/CT based on the radiolabeled sugar analogue [18F]-FDG is used to diagnose and stage pulmonary carcinoids, but is suboptimal due to low metabolic activity in these tumors. A new technique for pulmonary carcinoid imaging, using PET/CT with radiolabeled somatostatin analogs that specifically target somatostatin receptor subtype 2 (SSTR2), is becoming more standard, as many tumors overexpress SSTR2. However, pulmonary carcinoid patients with diminished SSTR2 expression are not eligible for this imaging or any type of SSTR2-specific treatment. We have found that histone deacetylase (HDAC) inhibitors can upregulate the expression of SSTR2 in pulmonary carcinoid cell lines. In this study, we used a non-cytotoxic dose of HDAC inhibitors to induce pulmonary carcinoid SSTR2 expression in which we confirmed in vitro and in vivo. A non-cytotoxic dose of the HDAC inhibitors: thailandepsin A (TDP-A), romidepsin (FK228), suberoylanilide hydroxamic acid (SAHA), AB3, and valproic acid (VPA) were administered to promote SSTR2 expression in pulmonary carcinoid cell lines and xenografts. This SSTR2 upregulation technique using HDAC inhibitors could enhance radiolabeled somatostatin analog-based imaging and the development of potential targeted treatments for pulmonary carcinoid patients with marginal or diminished SSTR2 expression. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |